Market Overview:
The global NASH biomarkers market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of NASH, rising awareness about NASH and its diagnosis, and technological advancements in the field of biomarkers. However, factors such as high costs associated with diagnosis and treatment of NASH may restrain the growth of this market. The global NASH biomarkers market can be segmented on the basis of type, application, and region. On the basis of type, the market can be divided into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers,, oxidative stress markers,, and others. Serum biomarkers are expected to account for a major share in this market owing to their wide use in diagnostics.Onthebasisofregion,.
 Biomarkers Industry Outlook.svg)
Product Definition:
NASH (Non-alcoholic Steatohepatitis) is a liver disease caused by fat accumulation in the liver, inflammation, and damage to the liver cells. The diagnosis of NASH is based on characteristic changes seen on a biopsy of the liver. There are no specific biomarkers for NASH currently available, but certain blood tests and imaging studies may be suggestive of the condition. The importance of NASH biomarkers is that they may help to identify patients who are at risk for progression to cirrhosis and/or hepatocellular carcinoma.
Serum biomarkers:
The global serum biomarkers, it's usage and growth factor in NASH (Non-alcoholic Steatohepatitis) Biomarkers market size was valued at USD 2.5 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period.
Hepatic fibrosis biomarkers:
Hepatic fibrosis biomarkers are substances that are produced in the liver and whose levels either increase or decrease, depending on the degree of liver damage. The most common ones are gamma-glutamyl transpeptidase (GGTP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
The use of these biomarkers for diagnosis has been approved by the U.S.
Application Insights:
The academic research institutes held the largest share of the global NASH biomarker market in 2017. This is attributed to growing prevalence of fatty liver and increasing number of researchers working towards identification of novel diagnostic markers for non-alcoholic steatohepatitis. Increasing research activities pertaining to mechanisms related to development and progression of NAFLD are also expected to contribute significantly towards growth during the forecast period.
The pharmaceutical & clinical research industry held a significant share owing to an increase in incidence rates coupled with awareness regarding diagnosis & treatment options for patients suffering from fatty liver disease. The industry is anticipated gain a major revenue share during the forecast period as there is an increased demand for drugs that can cure or prevent non- alcoholic fatty liver disease due largely on high prevalence rate across several countries worldwide including U.S.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of biotechnology and pharmaceutical companies, which are engaged in drug discovery and development processes for treating NASH. Moreover, these companies are also involved in clinical trials for developing novel therapeutics that target various pathways underlying NASH progression.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing prevalence of obesity coupled with rising disposable income among individuals leading to an increase in demand for medicines including NASH biomarkers-based therapies.
Key Companies Mentioned In This Report: AbbVie Inc.; Allergan; Amgen; Anika Therapeutics Ltd.
Growth Factors:
- Increasing prevalence of obesity and metabolic syndrome: The increasing prevalence of obesity and metabolic syndrome is a major growth driver for the NASH biomarkers market. According to the World Health Organization (WHO), in 2016, more than 1.9 billion adults were overweight, out of which 650 million were obese. Furthermore, the number of people with diabetes has almost quadrupled since 1980, reaching 422 million in 2014. This is expected to drive the demand for NASH biomarkers over the forecast period.
- Rising awareness about NASH: There is a growing awareness among healthcare professionals and patients about NASH and its associated risks. This is likely to boost demand for diagnostic tests for early detection of this condition over the forecast period.
- Technological advancements in diagnostics: The technological advancements in diagnostics are aiding in better detection of NASH at an earlier stage, thereby driving market growth during the forecast period.. For instance, recent advances such as metabolomics-based diagnosis are helping researchers identify new biomarkers that can be used to detect early-stage disease progression..
Scope Of The Report
Report Attributes
Report Details
Report Title
NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Research Report
By Type
Serum biomarkers, Hepatic fibrosis biomarkers, Apoptosis biomarkers, Oxidative stress biomarkers, Others
By Application
Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes
By Companies
GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim, Pfizer Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Report Segments:
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market is segmented on the basis of:
Types
Serum biomarkers, Hepatic fibrosis biomarkers, Apoptosis biomarkers, Oxidative stress biomarkers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GENFIT SA
- Gilead Sciences, Inc. (GILD)
- AstraZeneca
- Novartis AG
- Bristol-Myers Squibb Company
- Allergan Plc
- Novo Nordisk A/S
- Boehringer Ingelheim
- Pfizer Inc
 Biomarkers Market Overview.svg)
Highlights of The NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Serum biomarkers
- Hepatic fibrosis biomarkers
- Apoptosis biomarkers
- Oxidative stress biomarkers
- Others
- By Application:
- Pharma & CRO Industry
- Hospitals
- Diagnostic Labs
- Academic Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the NASH (Non-alcoholic Steatohepatitis) Biomarkers Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Biomarkers Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Some of the major players in the nash (non-alcoholic steatohepatitis) biomarkers market are GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim, Pfizer Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market - Supply Chain
4.5. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Forecast
4.5.1. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size (000 Units) and Y-o-Y Growth
4.5.3. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Absolute $ Opportunity
5. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Type
5.3.1. Serum biomarkers
5.3.2. Hepatic fibrosis biomarkers
5.3.3. Apoptosis biomarkers
5.3.4. Oxidative stress biomarkers
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Application
6.3.1. Pharma & CRO Industry
6.3.2. Hospitals
6.3.3. Diagnostic Labs
6.3.4. Academic Research Institutes
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand Share Forecast, 2019-2026
9. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Application
9.4.1. Pharma & CRO Industry
9.4.2. Hospitals
9.4.3. Diagnostic Labs
9.4.4. Academic Research Institutes
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Type
9.7.1. Serum biomarkers
9.7.2. Hepatic fibrosis biomarkers
9.7.3. Apoptosis biomarkers
9.7.4. Oxidative stress biomarkers
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand Share Forecast, 2019-2026
10. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Application
10.4.1. Pharma & CRO Industry
10.4.2. Hospitals
10.4.3. Diagnostic Labs
10.4.4. Academic Research Institutes
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Type
10.7.1. Serum biomarkers
10.7.2. Hepatic fibrosis biomarkers
10.7.3. Apoptosis biomarkers
10.7.4. Oxidative stress biomarkers
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand Share Forecast, 2019-2026
11. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Application
11.4.1. Pharma & CRO Industry
11.4.2. Hospitals
11.4.3. Diagnostic Labs
11.4.4. Academic Research Institutes
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe NSH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Type
11.7.1. Serum biomarkers
11.7.2. Hepatic fibrosis biomarkers
11.7.3. Apoptosis biomarkers
11.7.4. Oxidative stress biomarkers
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand Share, 2019-2026
12. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Application
12.4.1. Pharma & CRO Industry
12.4.2. Hospitals
12.4.3. Diagnostic Labs
12.4.4. Academic Research Institutes
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Type
12.7.1. Serum biomarkers
12.7.2. Hepatic fibrosis biomarkers
12.7.3. Apoptosis biomarkers
12.7.4. Oxidative stress biomarkers
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand Share, 2019-2026
13. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Application
13.4.1. Pharma & CRO Industry
13.4.2. Hospitals
13.4.3. Diagnostic Labs
13.4.4. Academic Research Institutes
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and Volume Forecast by Type
13.7.1. Serum biomarkers
13.7.2. Hepatic fibrosis biomarkers
13.7.3. Apoptosis biomarkers
13.7.4. Oxidative stress biomarkers
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand Share, 2019-2026
14. Competition Landscape
14.1. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Market Share Analysis
14.2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors and Customers
14.3. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GENFIT SA
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Gilead Sciences, Inc. (GILD)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AstraZeneca
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bristol-Myers Squibb Company
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Allergan Plc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novo Nordisk A/S
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Boehringer Ingelheim
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pfizer Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20
